Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 15/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020955 | 0.70 | DPP4 (0.41) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL5788518 | 0.69 | DPP4 (0.48) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL5804461 | 0.69 | NPC1 (0.50) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL5724293 | 0.69 | CRHR1 (0.37) | ADORA2AADORA1DPP4CRHR1DPP8 | |
| SCHEMBL5815735 | 0.68 | CRHR1 (0.49) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL6883642 | 0.67 | DPP4 (0.37) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL6816578 | 0.67 | DPP4 (0.39) | DPP4CRHR1NPC1DPP8DPP9 | |
| SCHEMBL5724420 | 0.67 | CRHR1 (0.48) | ADORA2AADORA1DPP4CRHR1DPP8 | |
| SCHEMBL6018979 | 0.67 | HSD17B10 (0.42) | DPP4CRHR1NPC1 | |
| SCHEMBL5724691 | 0.67 | CRHR1 (0.35) | ADORA2AADORA1DPP4CRHR1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622911-A2 | PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Pharmacia & Upjohn Company LLC (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040242587-A1 | Pyrrolo[1,2-b]pyridazine compounds | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| WO-2004099213-A2 | PYRROLO (1,2-B) PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1622911-A2 | PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Pharmacia & Upjohn Company LLC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040242587-A1 | Pyrrolo[1,2-b]pyridazine compounds | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
| WO-2004099213-A2 | PYRROLO (1,2-B) PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242587-A1 | Pyrrolo[1,2-b]pyridazine compounds | CRHR1, CRHR2, CRH | ADORA2A 128/4885ADORA1 67/4885DPP4 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.